The clinical information you need, at your fingertips.

Early real‑world data indicate greater relative lean tissue depletion with tirzepatide, not fully explained by greater weight loss alone. . .

Nirmatrelvir-ritonavir did not reduce already low rates of hospitalization or death, though it did shorten recovery time and lower viral load during treatment. . .

In two real-world studies of high-risk cardiology patients, tirzepatide was associated with fewer deaths and cardiovascular events after percutaneous coronary intervention or transcatheter aortic valve replacement. . .

An artificial intelligence model used single-cell tumor data to predict patient survival and identify the specific cell populations most closely tied to risk in melanoma and liver cancer. . .

A large VA cohort finds low absolute colorectal cancer risk after age 75, even with prior adenoma. . .

Study highlights strengths and limits of standard-dose intranasal naloxone against potent opioids. . .

A single pill combining three low-dose blood pressure medicines reduced recurrent stroke and major cardiovascular events in patients with intracerebral hemorrhage and elevated systolic blood pressure. . .

Phase 3 X-TOLE2 and 48-month extension results for azetukalner highlight robust efficacy in drug-resistant focal onset seizures. . .

Large UK study finds highest risk just before and shortly after treatment initiation, with dangerous amplification from common co prescriptions. . .